论文部分内容阅读
目的 建立HCV基因分型方法 ,研究HCV基因型与肝病程度的关系 ,探讨HCV基因型与IFN α2b抗病毒疗效的关系 .方法 HCV基因组NS5区PCR扩增产物酶切分型 .结果 73例HCV感染者中有HCVⅡ型 45例 ,HCVⅢ型 2 8例 .Ⅱ型HCV感染者中有慢性肝炎 31例 ,肝硬化 14例 ;Ⅲ型HCV感染者中有慢性肝炎 2 6例 ,肝硬化 2例 .Ⅱ型HCV感染者的肝硬化发生率显著高于Ⅲ型HCV感染者 (P <0 .0 5 ) .所有病人均应用IFN α2b治疗 .结论 Ⅱ型HCV感染者比Ⅲ型HCV感染者易导致肝硬化的发生 .丙肝患者应用IFN α2b治疗时 ,Ⅲ型HCV感染者的疗效好于Ⅱ型HCV感染者 .
Objective To establish a method of HCV genotyping to study the relationship between HCV genotypes and the degree of liver disease and to explore the relationship between HCV genotypes and antiviral effect of IFNα2b.Methods Enzyme-digesting genotyping of NS5 region of HCV genome was performed.Results 73 cases of HCV infection There were 45 cases of HCV Ⅱ type and 28 cases of HCV Ⅲ type.Among the type Ⅱ HCV infection, there were 31 cases of chronic hepatitis and 14 cases of liver cirrhosis.Among the type Ⅲ HCV infection, there were 26 cases of chronic hepatitis and 2 cases of liver cirrhosis.Ⅱ The incidence of cirrhosis in patients with HCV infection was significantly higher than that in patients with HCV infection (P <0.05) .All patients were treated with IFNα2b.Conclusion Type Ⅱ HCV infection is more likely to cause cirrhosis than type Ⅲ HCV infection Of hepatitis C patients treated with IFNα2b, HCV infection in patients with type III is better than type Ⅱ HCV infection.